A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans

Human Biology

Volumn 78, Issue 3, 2006, Pages 329-339

  Warren, D M ^a   Cole, S A ^a   Dyer, T D ^a   Soria, J M ^b   Souto, J C ^b   Fontcuberta, J ^b   Blangero, J ^a   MacCluer, J W ^a   Almasy, L ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Family study; Hemostasis; Linkage analysis; Quantitative trait loci; Thrombin activatable fibrinolysls inhibitor (TAFI)

Indexed keywords

FIBRIN; PLASMINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 9Q; DNA POLYMORPHISM; FEMALE; FIBRINOLYSIS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENOME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HISPANIC; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NORMAL HUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE TRAIT LOCUS; REGULATORY DNA SEQUENCE; SHORT TANDEM REPEAT; STRUCTURAL GENE; THROMBOSIS;

EID: 33845583473     PISSN: 00187143     EISSN: None     Source Type: Journal    
DOI: 10.1353/hub.2006.0049     Document Type: Article

References (33)

1. Almasy, L., and J. Blangero. 1998. Multipoint quantitative-trait linkage analysis in general pedigrees. Am. J. Hum. Genet. 62:1198-1211.
2. Ariëns, R. A., M. de Lange, H. Snieder et al. 2002. Activation markers of coagulation and fibrinolysis in twins: Heritability of the prethrombotic state. Lancet 359:667-671.
3. Bajzar, L., R. Manuel, and M. E. Nesheim. 1995. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270:14,477-14,484.
4. Bajzar, L., J. Morser, and M. Nesheim. 1996. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271:16,603-16,608.
5. Boffa, M. B., J. D. Hamill, D. Maret et al. 2003. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J. Biol. Chem. 278:9250-9257.
6. Boffa, M. B., T. S. Reid, E. Joo et al. 1999. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 38:6547-6558.
7. Brouwers, G. J., H. L. Vos, F. W. Leebeek et al. 2001. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98:1992-1993.
8. Buil, A., J. M. Soria, J. C. Souto et al. 2003. Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI). J. Thromb. Haemost. 1:P0794.
9. Chetaille, P., M. C. Alessi, D. Kouassi et al. 2000. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 83:902-905.
10. Crainich, P., Z. Tang, E. M. Macy et al. 2000. A polymorphism at position -438 in the promoter region of thrombin-activatable fibrinolysis inhibitor (TAFI) is strongly associated with plasma antigen levels in healthy older men and women [abstract]. Circulation 102:866.
11. Eaton, D. L., B. E. Malloy, S. P. Tsai et al. 1991. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266:21,833-21,838.
12. Feingold, E., P. O. Brown, and D. Siegmund. 1993. Gaussian models for genetic linkage analysis using complete high-resolution maps of identity by descent. Am. J. Hum. Genet. 53:234-251.
13. Franco, R. F., M. G. Fagundes, J. C. Meijers et al. 2001. Identification of polymorphisms in the 5′ untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis. Haemotologica 86:510-517.
14. Henry, M., H. Aubert, P. E. Morange et al. 2001. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97:2052-2058.
15. Juhan-Vague, I., P. E. Morange, H. Aubert et al. 2002. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22:867-873.
16. Juhan-Vague, I., J. F. Renucci, M. Grimaux et al. 2000. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler. Thromb. Vasc. Biol. 20:2156-2161.
17. Koschinsky, M. L., M. B. Boffa, M. E. Nesheim et al. 2001. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure. Clin. Genet. 60:345-349.
18. Mao, S. S., C. M. Cooper, T. Wood et al. 1999. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B: Modulation by glycosaminoglycans. J. Biol. Chem. 274:35,046-35,052.
19. Morange, P. E., I. Juhan-Vague, P. Y. Scarabin et al. 2003. Association between TAFI antigen and Alal47Thr polymorphism of the TAFI gene and the angina pectoris incidence: The PRIME study. Thromb. Haemost. 89:554-560.
20. Mosnier, L. O., P. A. von dem Borne, J. C. Meijers et al. 1998. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb. Haemost. 80:829-835.
21. Sato, T., T. Miwa, H. Akatsu et al. 2000. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J. Immunol. 165:1053-1058.
22. Schatteman, K. A., F. J. Goossens, S. S. Scharpe et al. 1999. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin. Chem. 45:807-813.
23. Schroeder, V., T. Chatterjee, H. Mehta et al. 2002. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb. Haemost. 88:1020-1025.
24. Silveira, A., K. Schatteman, F. Goossens et al. 2000. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84:364-368.
25. Stromqvist, M., K. Schatteman, J. Leurs et al. 2001. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb. Haemost. 85:12-17.
26. Tregouet, D. A., H. Aubert, M. Henry et al. 2001. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum. Genet. 109:191-197.
27. Tsai, S. P., and D. Drayna. 1992. The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13. Genomics 14:549-550.
28. Vanhoof, G., J. Wauters, K. Schatteman et al. 1996. The gene for human carboxypeptidase U (CPU)-proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics 38:454-455.
29. van Tilburg, N. H., F. R. Rosendaal, and R. M. Bertina. 2000. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855-2859.
30. Wang, W., M. B. Boffa, L. Bajzar et al. 1998. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 273:27,176-27,181.
31. Wang, W., D. F. Hendriks, and S. S. Scharpe. 1994. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 269:15,937-15,944.
32. World Health Organization. 1999. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Noncommunicable Disease Surveillance, World Health Organization, 1-59.
33. Yano, Y., N. Kitagawa, E. C. Gabazza et al. 2003. Increased plasma thrombin-activalable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 88:736-741.